Difference between kidney function by cystatin C versus creatinine and association with muscle mass and frailty.

Yuan JH, Rifkin DE, Ginsberg C, Cawthon PM, Kado DM, Bauer SR, Ensrud KE, Hoffman AR, Potok OA. Difference between kidney function by cystatin C versus creatinine and association with muscle mass and frailty. Journal of the American Geriatrics Society. 2024 May 31.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

BACKGROUND: A higher difference in estimated glomerular filtration rate by cystatin C versus creatinine (eGFRDiff = eGFRCys - eGFRCreat) is associated with decreased frailty risk. Since eGFRCreat is influenced by muscle more than eGFRCys, muscle mass may explain this association. Previous work could not account for this when considering regional muscle measures by imaging. Deuterated creatine (DCr) dilution measures whole body muscle mass (kilograms). We aimed to determine whether eGFRDiff is associated with DCr muscle mass and whether muscle mass explains the association between eGFRDiff and frailty. METHODS: Cross-sectional analysis within the multicenter MrOS Study at Year 14 (visit 4). 490 men of the original cohort of 5994 MrOS participants (aged 65 at enrollment) were included. Exposure was eGFRDiff ( = eGFRCys - eGFRCreat), calculated using CKD-EPI equations 2012/2021. Primary outcome was DCr muscle mass. Secondary outcome was phenotypic pre-frailty (one or two criteria) and frailty ( three criteria) including the following: weight loss, weakness, slow gait, physical activity, poor energy. The association of eGFRDiff with DCr muscle mass was examined by linear regression, that with prefrailty / frailty by multinomial logistic regression. RESULTS: Mean ± SD age was 84 ± 4 years, eGFRCreat 68 ± 16, eGFRCys 52 ± 16, eGFRDiff -15 ± 12 mL/min/1.73 m and DCr muscle mass 24 ± 4 kg. For each SD increment in eGFRDiff, D3Cr muscle mass was 1.4 kg higher on average, p < 0.0001 (fully adjusted). Higher eGFRDiff was associated with lower odds of frailty (OR = 0.63 95% CI [0.45;0.89]), but this was partially attenuated and insignificant after additionally adjusting for DCr muscle mass (OR = 0.85 95% CI [0.58; 1.24]). CONCLUSIONS: Higher eGFRDiff is associated with lower odds of frailty among late-life men. DCr muscle mass accounts for some of this association. This suggests that non-GFR determinants of creatinine and cystatin C, such as muscle mass, play a role in explaining the association of eGFRDiff with frailty. Future studies are needed to confirm.